Hormonal
Dual incretin agonists (specifically GIP/GLP-1 co-agonists like tirzepatide) produce significantly greater weight loss and glycemic reduction than single GLP-1 receptor agonists, effectively closing the treatment gap between pharmacotherapy and bariatric surgery.
If standard GLP-1 medications (like semaglutide or liraglutide) are not delivering sufficient weight loss or blood sugar control, or if side effects prevent you from taking a higher dose, ask your doctor about dual agonists like tirzepatide. These medications target two hormones (GIP and GLP-1) simultaneously and have shown in clinical trials to produce significantly greater weight loss (up to 20%) and better blood sugar control than single-hormone drugs, often with a manageable side effect profile.
This provides near double the weight loss to GLP-1 agonists and significant glucose lowering... dual agonists... hold the potential for marked metabolic benefits, mimicking that seen with bariatric surgery.
Why this rating
Based on multiple Phase III randomized controlled trials (SURPASS series) and FDA approval, though the paper is a narrative review.
Source
Harnessing the Incretin System with Multi-Agonists
Martin Whyte et al. · EMJ Innovation · 2022
DOI 10.33590/emjinnov/10115628
More from this paper
- GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and renal events compared to placebo, demonstrating cardiovascular and renal benefits beyond glycemic control.Good
- Dual GLP-1/Glucagon agonists (e.g., mazdutide, cotadutide, efinopegdutide) show promise for treating non-alcoholic steatohepatitis (NASH) and obesity, though with higher rates of gastrointestinal side effects compared to GLP-1 monotherapy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →